Alnylam Pharmaceuticals, Inc. ALNY gained 7% to $127.00 after the company announced positive 12-month clinical data from phase 2 study of Patisiran for patients with FAP. Share volume proved to be 217,000, compared to an all-day average of 757,000
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
